With the approval of the mTOR complex 1 (mTORC1) inhibitors Everolimus and Temsirolimus for breast cancer and renal cell carcinoma,55, 56 several inhibitors of PI3K/mTOR have been widely developed and clinical trials have been evaluated. Here, MTOR is linked to breast cancer.